参考文献/References:
[1] van Dorst DCH,Dobbin SJH,Neves KB,et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients[J]. Circ Res,2021, 128(7):1040-1061.
[2] Wang Y,Cui C,Ren X,et al. Cardiovascular toxicity associated with angiogenesis inhibitors:a comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021[J]. Front Cardiovasc Med,2022,9:988013.
[3] Abdel-Qadir H,Ethier JL,Lee DS,et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis[J].?Cancer Treat Rev,2017,53:120-127.
[4] Wang Z,Chen Z,Zhang L,et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015[J].?Circulation,2018,137(22):2344-2356.
[5] Hasan Khan M,Pathak S,Yadav U,et al. Hypertension in Cancer Survivors[J].?Curr Hypertens Rep, 2022,24(10):435-443.
[6] Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [J].?Eur Heart J,2022,43(41):4229-4361.
[7] Motzer RJ,Hutson TE,Tomczak P,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med,2007,356(2):115-124.
[8] Beavers CJ,Rodgers JE,Bagnola AJ,et al. Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association[J].?Circulation,2022,145(15):e811-e838.
[9] Versmissen J,Mirabito Colafella KM,Koolen SLW,et al. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension[J].?Cardiovasc Res,2019,115(5):904-914.
[10] Barta P,Kamaraj R,Kucharova M,et al. Preparation,?In Vitro?Affinity, and?In Vivo?Biodistribution of Receptor-Specific?68Ga-Labeled Peptides Targeting Vascular Endothelial Growth Factor Receptors[J].?Bioconjug Chem,2022,33(10):1825-1836.
[11]Sewduth R,Santoro MM. "Decoding" Angiogenesis: New Facets Controlling Endothelial Cell Behavior[J].?Front Physiol,2016,7:306.
[12]Vincenti V,Cassano C,Rocchi M,et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3[J].?Circulation,1996,93(8):1493-1495.
[13] Elebiyo TC,Rotimi D,Evbuomwan IO,et al. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy[J].?Cancer Treat Res Commun,2022,32:100620.
[14] Melincovici CS,Bo?ca AB,?u?man S,et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis[J].?Rom J Morphol Embryol,2018,59(2):455-467.
[15] Tsien CI,Pugh SL,Dicker AP,et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma[J].?J Clin Oncol,2023,41(6):1285-1295.
[16] Niu G,Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy[J].?Curr Drug Targets,2010,11(8):1000-1017.
[17] Camarda N,Travers R,Yang VK ,et al. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications[J].?Curr Oncol Rep,2022,24(4):463-474.
[18] Karlstaedt A,Moslehi J,de Boer RA. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer[J].?Nat Rev Cardiol,2022,19(6):414-425.
[19] Grela-Wojewoda A,Pacholczak-Madej R,Adamczyk A,et al. Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer[J].?Int J Mol Sci,2022,23(5):2815.
[20] Robinson ES,Khankin EV,Choueiri TK,et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors[J].?Hypertension,2010,56(6):1131-1136.
[21] Mazzuca MQ,Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease[J].?Biochem Pharmacol,2012,84(2):147-162.
[22] Kappers MH,de Beer VJ,Zhou Z,et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress[J].?Hypertension,2012,59(1):151-157.
[23] Mirabito Colafella KM,Neves KB,Montezano AC,et al. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats[J].?Cardiovasc Res,2020,116(10):1779-1790.
[24] Li C,Ma L,Wang Q,et al. Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension[J].?J Hypertens,2022,40(4):675-684.
[25] Wang W,He Q,Li C,et al. Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer[J].?Front Cardiovasc Med,2022,9:873829.
[26] Yang Q,Xu J,Gu J,et al. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications[J].?Adv Sci (Weinh),2022,9(34):e2201609.
[27] Todorova D,Simoncini S,Lacroix R,et al. Extracellular Vesicles in Angiogenesis[J].?Circ Res,2017,120(10):1658-1673.
[28] Neves KB,Rios FJ,Sevilla-Montero J,et al. Exosomes and the cardiovascular system: role in cardiovascular health and disease[J], Physiol,2022,10.1113/JP282054.
[29] Wang C,Wu H,Xing Y,et al. Endothelial-derived extracellular microRNA-92a promotes arterial stiffness by regulating phenotype changes of vascular smooth muscle cells[J].?Sci Rep,2022,12(1):344.
[30] Neves KB,Rios FJ,Jones R,et al. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury[J].?Cardiovasc Res,2019,115(5):978-988.
[31] Campia U,Moslehi JJ,Amiri-Kordestani L,et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association[J].?Circulation,2019,139(13):e579-e602.
[32] Zhang ZY,Li Y,Li R,et al. Tetrahydrobiopterin Protects against Radiation-induced Growth Inhibition in H9c2 Cardiomyocytes[J].?Chin Med J (Engl),2016,129(22):2733-2740.
[33] Neves KB,Rios FJ,van der Mey L,et al. VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes[J].?Hypertension,2018,71(4):638-647.
[34] Wang W,He Q,Zhuang C,et al. Apatinib Through Activating the RhoA/ROCK Signaling Pathway to Cause Dysfunction of Vascular Smooth Muscle Cells[J].?Appl Biochem Biotechnol,2022,194(11):5367-5385.
[35] Steeghs N,Gelderblom H,Roodt JO,et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor[J].?Clin Cancer Res,2008,14(11):3470-3476.
[36] Mourad JJ,des Guetz G,Debbabi H,et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation[J].?Ann Oncol,2008,19(5):927-934.
[37] Wheeler-Jones C,Abu-Ghazaleh R,Cospedal R,et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase[J].?FEBS Lett,1997,420(1):28-32.
[38] Mirabito Colafella KM,van Dorst DCH,Neuman RI,et al. Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage[J].?Clin Sci (Lond),2022,136(9):675-694.
[39] Catino AB,Hubbard RA,Chirinos JA,et al. Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma[J].?Circ Heart Fail,2018,11(3):e004408.
[40] Veronese ML,Mosenkis A,Flaherty KT,et al. Mechanisms of hypertension associated with BAY 43-9006[J].?J Clin Oncol,2006,24(9):1363-1369.
[41] Humphrey JD,Harrison DG,Figueroa CA,et al. Central Artery Stiffness in Hypertension and Aging: A Problem With Cause and Consequence[J].?Circ Res,2016,118(3):379-381.
[42] Lankhorst S,Severs D,Markó L,et al. Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation? [J].?Hypertension,2017,69(5):919-926.
[43] Tsai SH,Lu G,Xu X,et al. Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy[J].?Cardiovasc Res,2017,113(11):1329-1337.
[44] Shiau JP,Chuang YT,Tang JY,et al. The Impact of Oxidative Stress and AKT Pathway on Cancer Cell Functions and Its Application to Natural Products[J].?Antioxidants (Basel),2022,11(9):1845.
[45] Wolfrum S,Dendorfer A,Rikitake Y,et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection[J].?Arterioscler Thromb Vasc Biol,2004,24(10):1842-1847
[46] Versmissen J,van Doorn L,Mirabito Colafella KM,et al. Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy[J].?J Hypertens,2018,36(11):2279-2280.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(9):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(9):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(9):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(9):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(9):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]